Clinical Trials
116 trialsAutologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
National Institutes of Health Clinical Center (CC)
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
GlaxoSmithKline
A Phase 2 Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Guangzhou Lupeng Pharmaceutical Company LTD.
FORWARD
CareDx
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sun Yat-sen University
STARLING
Indiana University
ALT-101
Allterum Therapeutics, Inc
Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
IASO207 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Peking University People's Hospital
QiNKT-HSCT
University Hospital Pilsen
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
Regeneron Pharmaceuticals
ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
Regeneron Pharmaceuticals
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Fondazione Italiana Linfomi - ETS
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Shanghai Jiao Tong University School of Medicine
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
National Cancer Institute, Egypt
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
Kousai Bio Co., Ltd.
Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies
Institute of Hematology & Blood Diseases Hospital, China
STRAP
National Cancer Centre, Singapore
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
FUMANBA-04
Nanjing IASO Biotechnology Co., Ltd.
EpiRev-NKT
Fudan University
Predicting Recurrence in HR+/HER2- Early Breast Cancer
Shengjing Hospital
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
Tcelltech Inc.
EINSTEIN-TNBC
Sunnybrook Health Sciences Centre
PiloPedia
University Hospital, Angers
PRiME II
Washington University School of Medicine
EPPIL
Institut Jean-Godinot
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
Huazhong University of Science and Technology
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia
University of Rochester
A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
SL4903
Institute of Hematology & Blood Diseases Hospital, China
CALM-TF
University Health Network, Toronto
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer
Zhongnan Hospital
HFUS-CLEAR
Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
Tongji Hospital
Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Tongji Hospital
LidCRM
First Affiliated Hospital of Ningbo University
Mezi-KD
Assistance Publique - Hôpitaux de Paris
Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors
The First Affiliated Hospital with Nanjing Medical University
GABRIEL
Medical College of Wisconsin
125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors
Jinan Military General Hospital
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Affiliated Hospital of Jiangsu University
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
Peking University People's Hospital
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
Affiliated Hospital of Jiangsu University